Outcome of the Board Meeting held on 13th November, 2025 for approval of un-audited result as on 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chandra Bhagat Pharma's H1 FY26 (Apr–Sep 2025) revenue came in at ₹25.55 crore, a sharp ~60% decline from ₹64.92 crore in H1 FY25. Despite the steep fall in top line, the company remained profitable with profit before tax of ₹58.62 lakhs (vs ₹61.25 lakhs) and profit after tax of ₹44.91 lakhs (vs ₹68.49 lakhs, a ~34% drop). EBITDA-style margins expanded meaningfully as cost of materials and other expenses were scaled down faster than revenue. Operating cash flow turned around from a ₹728.10 lakh outflow last year to a ₹96.81 lakh inflow this year, helped by better collections and lower payables. Statutory auditor A Y & Company issued a clean (unqualified) limited review report; no exceptional items, auditor changes, or investor complaints were reported.
The steep revenue slump is a red flag, but strict cost control, expanding margins, and a return to positive operating cash flow cushion the picture. Stock reaction will likely hinge on whether revenue stabilises in the second half of FY26.